“With last week’s FDA approval, we are experiencing strong demand for Motiva implants — both from surgeons and patients,” said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. “The FDA approval came as we attended the annual conference of the American Society of Plastic Surgeons. The response has been overwhelming and our team has already spoken to over 400 plastic surgeons since the announcement.
“Since approval, we have already doubled our team to 25 sales representatives across the United States, and our story of true innovation, backed by science and data, resonates strongly. Everything we’re seeing suggests we can be the implant of choice in the United States.”
Costa Rica-based Establishment Labs is a medical technology company dedicated to improving women’s health and wellness, primarily in breast aesthetics and reconstruction.
Calobrace and Caroline A. Glicksman, MD, a board-certified plastic surgeon based in New Jersey, performed the first surgeries following last week’s U.S. Food and Drug Administration approval of Motiva® SmoothSilk® Ergonomix and Motiva SmoothSilk Round breast implants in primary and revision breast augmentation.
“I have many patients who have been waiting a long time for Motiva to be approved, in some cases for years,” said Dr. Calobrace. “I was very happy to have one of the first Motiva breast augmentations in the United States. The innovation in these devices not only improves aesthetic outcomes, but also significantly lowers the complication rates we see with other devices. Motiva implants are a game changer.”
Calobrace is a board-certified plastic surgeon and a member of the American Society of Plastic Surgeons, the Society of Aesthetics, the International Society of Aesthetic Plastic Surgery, and the Kentucky Society of Plastic Surgeons. He holds dual clinical faculty appointments with the Departments of Plastic Surgery, University of Louisville and University of Kentucky, and received teaching honors in 2007, 2011, 2014, 2015, 2016, and 2019.
Motiva implants feature the SmoothSilk surface, which is designed for enhanced biocompatibility and has been scientifically proven to promote low inflammation. These 6th generation implants are offered in two different implant styles. Motiva SmoothSilk Ergonomix is the world’s first breast implant to incorporate the science of ergonomics as it is designed to react, feel and move like natural breast tissue. Uniquely, their shape can adjust as the body changes position, maintaining a round shape when lying down and a teardrop shape when standing. Motiva SmoothSilk round implants provide increased fullness and softness to the upper breast while maintaining a round full shape regardless of position.
“The plastic surgery community has waited more than a decade to offer breast augmentation patients in the United States something truly new,” said Dr. Glixman, medical director of the Motiva US IDE study and clinical trial investigator. “Now, we can confidently offer our patients implants that consistently show low complication rates and high patient satisfaction.”
More information about Motiva breast implants can be found at motivausa.com.
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The nearly four million Motivas® devices that Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have set a new standard for patient safety and satisfaction in the more than 85 countries in which they are available.
More Kentucky business news here.
